Takeaway

• The US Food and Drug Administration (FDA) has approved ivosidenib for the treatment of adults with previously treated locally advanced or metastatic isocitrate dehydrogenase-1 (IDH1)-mutated cholangiocarcinoma (CCA).

Why this matters

• Ivosidenib is the first targeted therapy approved for IDH1-mutated CCA, a condition that affects nearly 8000 individuals in the...